Lido Advisors LLC Sells 743 Shares of IDEXX Laboratories, Inc. $IDXX

Lido Advisors LLC reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 19.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,141 shares of the company’s stock after selling 743 shares during the quarter. Lido Advisors LLC’s holdings in IDEXX Laboratories were worth $1,640,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Aurora Investment Managers LLC. purchased a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $2,442,000. National Pension Service lifted its position in shares of IDEXX Laboratories by 5.6% during the second quarter. National Pension Service now owns 129,305 shares of the company’s stock worth $68,071,000 after purchasing an additional 6,885 shares in the last quarter. Howard Capital Management LLC purchased a new position in shares of IDEXX Laboratories in the third quarter valued at $1,249,000. NewEdge Advisors LLC boosted its stake in shares of IDEXX Laboratories by 60.9% in the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock valued at $8,552,000 after purchasing an additional 5,761 shares during the period. Finally, Arizona State Retirement System boosted its stake in shares of IDEXX Laboratories by 4.9% in the second quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock valued at $11,988,000 after purchasing an additional 1,074 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on IDXX shares. Barclays lowered their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a report on Tuesday, November 3rd. BTIG Research dropped coverage on shares of IDEXX Laboratories in a research report on Friday, October 30th. They issued a “buy” rating for the company. UBS Group raised their target price on IDEXX Laboratories from $627.00 to $700.00 and gave the company a “neutral” rating in a research note on Tuesday, November 3rd. Finally, Jefferies Financial Group dropped their target price on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a research report on Tuesday, October 20th. Seven equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $717.27.

Check Out Our Latest Stock Report on IDXX

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $704.23 on Monday. The business’s 50 day moving average is $562.41 and its two-hundred day moving average is $573.52. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98. The firm has a market cap of $55.49 billion, a price-to-earnings ratio of 47.49 and a beta of 1.55. The company has a quick ratio of 0.88, a current ratio of 1.19 and a debt-to-equity ratio of 0.16.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same period in the prior year, the business posted $3.22 EPS. The business’s revenue was up 9.9% on a year-over-year basis. Analysts forecast that IDEXX Laboratories, Inc. will post 15.05 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In related news, insider Jonathan Mazelsky sold 25,140 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $703.19, for a total value of $17,678,196.60. Following the sale, the insider directly owned 83,803 shares of the company’s stock, valued at $58,929,431.57. This represents a 23.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director owned 9,568 shares in the company, valued at $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 41,428 shares of company stock valued at $28,567,934 over the last ninety days. 0.79% of the stock is currently owned by corporate insiders.

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Read More

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.